Zymeworks Inc.
Ziihera
gastroesophageal adenocarcinoma (GEA)
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for Ziihera in gastroesophageal adenocarcinoma (GEA) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“In November 2025, together with our partners Jazz and BeOne, we announced positive topline results from the Phase 3 HERIZON-GEA-01 trial supporting Ziihera as the potential HER2-targeted agent-of-choice and new standard of care in first-lin”